METHOD OF TREATING FUNCTIONAL BOWEL DISORDERS

WIPO Patent Application WO2004062623

A3

The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.

LANDAU STEVEN B (US)

PCT/US2004/000807

June 09, 2005

January 13, 2004

Click for automatic bibliography generation  

DYNOGEN PHARMACEUTICALS INC (US)
LANDAU STEVEN B (US)

A01N43/00; A01N43/54; A61K31/505; A61K31/519; A61K31/55; A61K31/551; A61K45/06; A61K; (IPC1-7): A01N43/00; A01N43/54; A61K31/505; A61K31/55

US20020039599A1	2002-04-04
US6475078B1	2002-11-05

EGUCHI ET AL.: "The anxiolytic-like effect of MCI-225, a selective NA renptake inhibitor with 5-HT3 receptor antagonism", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 68, 2001, pages 677 - 683, XP002239887
"How to avoid a health insurance claim denial- and what to when you can't", INSURE.COM, 3 January 2002 (2002-01-03), pages 4, XP002986530, Retrieved from the Internet
See also references of EP 1558081A4

View/Download PDF      PDF Help

Previous Patent: PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF

Next Patent: METHOD OF TREATING NAUSEA, VOMITING, RETCHING OR ANY COMBINATION THEREOF